Neurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $112.00 at Wedbush

Neurocrine Biosciences (NASDAQ:NBIX) had its target price trimmed by Wedbush from $126.00 to $112.00 in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other analysts have also recently commented on NBIX. Mizuho boosted their price target on Neurocrine Biosciences from $117.00 to $119.00 and gave the stock a neutral rating in a research report on Friday, February 5th. Zacks Investment Research cut Neurocrine Biosciences from a buy rating to a hold rating in a research report on Thursday, April 15th. Raymond James initiated coverage on Neurocrine Biosciences in a research report on Monday, February 1st. They issued an outperform rating and a $163.00 price target on the stock. Canaccord Genuity reaffirmed a buy rating on shares of Neurocrine Biosciences in a research report on Thursday, January 21st. Finally, William Blair reaffirmed a buy rating on shares of Neurocrine Biosciences in a research report on Tuesday, January 26th. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $127.68.

NBIX stock opened at $96.16 on Monday. The business’s 50 day moving average price is $95.06 and its two-hundred day moving average price is $100.44. Neurocrine Biosciences has a fifty-two week low of $86.02 and a fifty-two week high of $136.26. The company has a market capitalization of $9.09 billion, a price-to-earnings ratio of 103.40 and a beta of 1.01.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 3rd. The company reported $3.58 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $2.99. Neurocrine Biosciences had a return on equity of 18.18% and a net margin of 8.96%. The firm had revenue of $247.90 million for the quarter, compared to analysts’ expectations of $260.43 million. Research analysts forecast that Neurocrine Biosciences will post 1.24 earnings per share for the current year.

In other news, Director Gary A. Lyons sold 1,600 shares of the company’s stock in a transaction on Monday, January 25th. The stock was sold at an average price of $120.03, for a total value of $192,048.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Malcolm Lloyd-Smith sold 1,700 shares of the company’s stock in a transaction on Wednesday, February 10th. The stock was sold at an average price of $119.96, for a total value of $203,932.00. Following the completion of the sale, the insider now owns 33,610 shares of the company’s stock, valued at $4,031,855.60. The disclosure for this sale can be found here. Insiders have sold a total of 23,426 shares of company stock worth $2,740,985 over the last three months. Insiders own 4.30% of the company’s stock.

Several large investors have recently bought and sold shares of the company. DSM Capital Partners LLC increased its stake in shares of Neurocrine Biosciences by 33.4% in the 4th quarter. DSM Capital Partners LLC now owns 1,116,380 shares of the company’s stock worth $107,006,000 after purchasing an additional 279,614 shares in the last quarter. Norges Bank purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $67,804,000. Brown Advisory Inc. increased its stake in Neurocrine Biosciences by 8.5% in the 4th quarter. Brown Advisory Inc. now owns 697,730 shares of the company’s stock worth $66,878,000 after buying an additional 54,588 shares in the last quarter. Eaton Vance Management increased its stake in Neurocrine Biosciences by 310.8% in the 4th quarter. Eaton Vance Management now owns 528,489 shares of the company’s stock worth $50,656,000 after buying an additional 399,834 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Neurocrine Biosciences by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,521 shares of the company’s stock worth $45,483,000 after buying an additional 3,989 shares in the last quarter. Hedge funds and other institutional investors own 95.25% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc, a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids.

Read More: What is the Coverage Ratio?

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.